MDT

96.24

+0.35%↑

VEEV

285.71

-0.58%↓

A

138.04

-0.83%↓

HQY

94.48

+2.41%↑

PHR.US

22.63

+2.72%↑

MDT

96.24

+0.35%↑

VEEV

285.71

-0.58%↓

A

138.04

-0.83%↓

HQY

94.48

+2.41%↑

PHR.US

22.63

+2.72%↑

MDT

96.24

+0.35%↑

VEEV

285.71

-0.58%↓

A

138.04

-0.83%↓

HQY

94.48

+2.41%↑

PHR.US

22.63

+2.72%↑

MDT

96.24

+0.35%↑

VEEV

285.71

-0.58%↓

A

138.04

-0.83%↓

HQY

94.48

+2.41%↑

PHR.US

22.63

+2.72%↑

MDT

96.24

+0.35%↑

VEEV

285.71

-0.58%↓

A

138.04

-0.83%↓

HQY

94.48

+2.41%↑

PHR.US

22.63

+2.72%↑

Search

Ocular Therapeutix Inc

Open

SectorHealthcare

11.59 -3.26

Overview

Share price change

24h

Current

Min

11.45

Max

12.22

Key metrics

By Trading Economics

Income

-3.8M

-68M

Sales

2.8M

13M

Profit margin

-503.856

Employees

274

EBITDA

146K

-64M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+76.83% upside

Dividends

By Dow Jones

Next Earnings

13 Nov 2025

Market Stats

By TradingEconomics

Market Cap

357M

2.3B

Previous open

14.85

Previous close

11.59

News Sentiment

By Acuity

28%

72%

72 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Ocular Therapeutix Inc Chart

Past performance is not a reliable indicator of future results.

Related News

13 Oct 2025, 21:45 UTC

Acquisitions, Mergers, Takeovers

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million -- Update

13 Oct 2025, 21:07 UTC

Acquisitions, Mergers, Takeovers

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million

13 Oct 2025, 17:03 UTC

Major Market Movers

Canaan ADRs Climb on Launch of Gas-to-Computing Pilot in Canada

13 Oct 2025, 23:53 UTC

Market Talk

Gold Rises, Buoyed by Bullish Fundamental Backdrop -- Market Talk

13 Oct 2025, 23:39 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

13 Oct 2025, 22:15 UTC

Market Talk

Global Equities Roundup: Market Talk

13 Oct 2025, 22:15 UTC

Market Talk

Precinct Properties NZ's Equity Raising Looks Opportunistic -- Market Talk

13 Oct 2025, 21:57 UTC

Acquisitions, Mergers, Takeovers

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

13 Oct 2025, 21:36 UTC

Market Talk

Global Equities Roundup: Market Talk

13 Oct 2025, 21:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13 Oct 2025, 21:36 UTC

Market Talk

Fletcher's Near-Term Headwinds Don't Cloud Earnings Opportunity -- Market Talk

13 Oct 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

Goldman Sachs to Acquire Industry Ventures for Up to $965M -- Update

13 Oct 2025, 21:06 UTC

Acquisitions, Mergers, Takeovers

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

13 Oct 2025, 20:52 UTC

Acquisitions, Mergers, Takeovers

Goldman Sachs to Acquire Industry Ventures for Up to $965M

13 Oct 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

13 Oct 2025, 20:35 UTC

Acquisitions, Mergers, Takeovers

Goldman Expects to Close Deal in 1Q

13 Oct 2025, 20:34 UTC

Acquisitions, Mergers, Takeovers

Industry Ventures Will Be Part of Goldman's External Manager Platform, External Investing Group

13 Oct 2025, 20:33 UTC

Acquisitions, Mergers, Takeovers

Industry Ventures Currently Manages $7B of Assets Under Supervision

13 Oct 2025, 20:32 UTC

Acquisitions, Mergers, Takeovers

Goldman Sachs: Deal to Include Up to $300M of Additional Contingent Consideration Based on Future Performance Through 2030

13 Oct 2025, 20:31 UTC

Acquisitions, Mergers, Takeovers

Goldman Sachs: Consideration to Include $665M Cash and Equity Payable at Closing

13 Oct 2025, 20:29 UTC

Acquisitions, Mergers, Takeovers

Goldman Sachs to Buy VC Firm Industry Ventures

13 Oct 2025, 19:05 UTC

Market Talk

Oil Futures Pick Up on Easing U.S.-China Tension -- Market Talk

13 Oct 2025, 18:59 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

13 Oct 2025, 18:26 UTC

Market Talk

Precious Metals Close at New Record Highs -- Market Talk

13 Oct 2025, 18:10 UTC

Market Talk

Global Equities Roundup: Market Talk

13 Oct 2025, 18:10 UTC

Market Talk

Broadcom's OpenAI Deal Highlights AI Opportunity -- Market Talk

13 Oct 2025, 17:05 UTC

Market Talk

Global Equities Roundup: Market Talk

13 Oct 2025, 17:05 UTC

Market Talk

OpenAI Deal Offers Huge Upside to Broadcom's Earnings -- Market Talk

13 Oct 2025, 16:03 UTC

Acquisitions, Mergers, Takeovers

Umicore Completes Sale, Subsequent Lease-in of Permanent Gold Inventories

13 Oct 2025, 15:35 UTC

Market Talk

Precious Metals Push Record Highs Further -- Market Talk

Peer Comparison

Price change

Ocular Therapeutix Inc Forecast

Price Target

By TipRanks

76.83% upside

12 Months Forecast

Average 20.83 USD  76.83%

High 31 USD

Low 14 USD

Based on 13 Wall Street analysts offering 12 month price targets forOcular Therapeutix Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

13

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

6.97 / 7.62Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

72 / 371 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
help-icon Live chat